Tigermed Receives MSCI ESG AAA Rating
MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.
Environmental:
Tigermed has set science-based targets for reducing greenhouse gas emissions, which have been validated by the Science Based Targets initiative (SBTi). The company has implemented a comprehensive environmental management system, improved monitoring of emissions and resource utilization, and adopted digital platforms and green office initiatives to promote environmental sustainability.
Social:
W has advanced its digital transformation and leveraged AI technologies to enhance clinical trial efficiency. In 2024, Tigermed invested
Corporate Governance:
Tigermed has strengthened its ESG governance and compliance framework. The board of directors oversees all ESG-related matters, and the Compliance and ESG Committee is directly led by the General Manager and managed by the Chief Compliance Officer. ESG performance is incorporated into the General Manager's compensation structure. All employees receive 100% coverage of business ethics training, and new suppliers are required to sign the Supplier Code of Conduct upon onboarding, followed by regular assessments.
Since receiving its first MSCI ESG rating in 2020, Tigermed has consistently improved its performance, moving from a baseline rating to AA in 2023 and now achieving AAA. This progress reflects our ongoing investment in talent development, safety and quality management, carbon reduction, and ethical business practices.
This AAA rating marks a new milestone in our ESG journey. We will continue to strengthen our ESG governance framework, refine our management systems, and drive sustainable growth. As a company committed to "Serving Innovation,
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across
Learn more at www.tigermedgrp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tigermed-receives-msci-esg-aaa-rating-302532966.html
SOURCE Tigermed
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Silvercorp reports a Mineral Reserve increase of 50% in tonnes and 20% in silver ounces for the Ying Mining District
- BRAEMAR HOTELS & RESORTS ANNOUNCES CONCLUSION OF STRATEGIC REVIEW PROCESS AND PLAN TO BECOME A SELF-MANAGED REIT AND REMAIN PUBLICLY TRADED
- Willow Laboratories Welcomes Dr. Jill Biden, Ken Buck, and Said Hilal to Willow's Board of Directors
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share
